Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1993-04-22
1994-06-07
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
514558, A61K 3120
Patent
active
053189914
ABSTRACT:
Reduction of urinary calcium excretion in humans or animals by the administration of GLA or DGLA as much or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, is also useful in the treatment of nephrocalcinosis, renal stones and osteoporosis.
REFERENCES:
patent: 4816483 (1989-03-01), Georgieva et al.
patent: 4855136 (1989-08-01), Horrobin et al.
patent: 5116624 (1992-05-01), Horrobin et al.
Patent Abstracts of Japan vol. 13, No. 419 (C-637) [3767], Sep. 1989 & JP-A-1 157 912 (Nippon Oil & Fats Co., Ltd.) Jun. 1989.
Buck Alfred C.
Horrobin David F.
Criares T. J.
Efamol Holdings PLC
Waddell Frederick E.
LandOfFree
Fatty acid treatment to reduce calcium excretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fatty acid treatment to reduce calcium excretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fatty acid treatment to reduce calcium excretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-792944